Evidence map›Paper›PMID 37568818›Full record

ArticleCancers2023

Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks.

Sandra Ortega-Martorell, Ivan Olier, Orlando Hernandez, Paula D Restrepo-Galvis, Ryan A A Bellfield, Ana Paula Candiota

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sandra Ortega-MartorellData Science Research Centre, Liverpool John Moores University, Liverpool L3 3AF, UK.ORCID 0000-0001-9927-3209
Ivan OlierData Science Research Centre, Liverpool John Moores University, Liverpool L3 3AF, UK.ORCID 0000-0002-5679-7501
Orlando HernandezEscuela Colombiana de Ingeniería Julio Garavito, Bogota 111166, Colombia.
Paula D Restrepo-GalvisEscuela Colombiana de Ingeniería Julio Garavito, Bogota 111166, Colombia.
Ryan A A BellfieldData Science Research Centre, Liverpool John Moores University, Liverpool L3 3AF, UK.ORCID 0000-0002-9945-914X
Ana Paula CandiotaCentro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina, 08193 Cerdanyola del Vallès, Spain.ORCID 0000-0002-1523-6505

Funding

Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina CB06/01/0010Ministerio de Ciencia e Innovación PID2020-113058GB-I00
6 · The paper itself

Abstract

backgroundGlioblastoma (GB) is a malignant brain tumour that is challenging to treat, often relapsing even after aggressive therapy. Evaluating therapy response relies on magnetic resonance imaging (MRI) following the Response Assessment in Neuro-Oncology (RANO) criteria. However, early assessment is hindered by phenomena such as pseudoprogression and pseudoresponse. Magnetic resonance spectroscopy (MRS/MRSI) provides metabolomics information but is underutilised due to a lack of familiarity and standardisation.

methodsThis study explores the potential of spectroscopic imaging (MRSI) in combination with several machine learning approaches, including one-dimensional convolutional neural networks (1D-CNNs), to improve therapy response assessment. Preclinical GB (GL261-bearing mice) were studied for method optimisation and validation.

resultsThe proposed 1D-CNN models successfully identify different regions of tumours sampled by MRSI, i.e., normal brain (N), control/unresponsive tumour (T), and tumour responding to treatment (R). Class activation maps using Grad-CAM enabled the study of the key areas relevant to the models, providing model explainability. The generated colour-coded maps showing the N, T and R regions were highly accurate (according to Dice scores) when compared against ground truth and outperformed our previous method.

conclusionsThe proposed methodology may provide new and better opportunities for therapy response assessment, potentially providing earlier hints of tumour relapsing stages.

Indexed as

class activation mappingconvolutional neural networksdeep learningglioblastomaGrad-CAMmagnetic resonance spectroscopypreclinical modelstemozolomidetherapy response

Identifiers

PMID37568818
PMCPMC10417313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.